The study, called TRAMmoniTTR, will longitudinally monitor the clinical status of both symptomatic and asymptomatic participants with variants in the TTR gene.
The firm said it would use the funding to grow its client base and further R&D programs using machine learning for biomarker discovery and precision medicine.
The publisher of the Science family of journals will allow some authors to place peer-reviewed versions of their papers into publicly accessible repositories.